Halstenson C E, Hirata C A, Heim-Duthoy K L, Abraham P A, Matzke G R
Drug Evaluation Unit, Hennepin County Medical Center, Minneapolis, Minnesota 55415.
Antimicrob Agents Chemother. 1990 Jan;34(1):128-33. doi: 10.1128/AAC.34.1.128.
The effect of piperacillin administration on the dispositions of netilmicin and tobramycin was assessed in 12 chronic hemodialysis patients. Six subjects each received netilmicin (2 mg/kg) or tobramycin (2 mg/kg) alone and in combination with piperacillin (4 g every 12 h for four doses). Subjects also received a single dose of piperacillin (4 g) on a separate occasion. The serum concentration-versus-time profiles of netilmicin and tobramycin were biexponential. The terminal elimination half-life (t1/2 beta) of tobramycin was markedly reduced (59.62 +/- 25.18 [mean +/- standard deviation] versus 24.71 +/- 5.41 h) and total body clearance (CLP) was significantly increased in the presence of piperacillin (3.45 +/- 1.61 versus 7.16 +/- 1.64 ml/min). In contrast, the t1/2 beta (41.80 +/- 13.24 versus 40.07 +/- 10.37 h) and CLP (5.11 +/- 2.15 versus 5.55 +/- 2.32 ml/min) of netilmicin were not significantly altered when netilmicin was administered in combination with piperacillin. No change in the central or steady-state volume of distribution of netilmicin or tobramycin was observed. The disposition of piperacillin in hemodialysis patients was not altered in the presence of either aminoglycoside antibiotic. Although no adjustment in netilmicin dosing is required, tobramycin should be administered more frequently when given concomitantly with piperacillin to hemodialysis patients to avoid prolonged periods of subtherapeutic concentrations.
在12名慢性血液透析患者中评估了哌拉西林给药对奈替米星和妥布霉素处置的影响。6名受试者分别单独接受奈替米星(2mg/kg)或妥布霉素(2mg/kg),以及与哌拉西林联合使用(每12小时4g,共4剂)。受试者还在另一个时间点接受了单剂量的哌拉西林(4g)。奈替米星和妥布霉素的血清浓度-时间曲线为双指数曲线。在有哌拉西林存在的情况下,妥布霉素的终末消除半衰期(t1/2β)显著缩短(59.62±25.18[平均值±标准差]对24.71±5.41小时),全身清除率(CLP)显著增加(3.45±1.61对7.16±1.64ml/分钟)。相比之下,当奈替米星与哌拉西林联合给药时,奈替米星的t1/2β(41.80±13.24对40.07±10.37小时)和CLP(5.11±2.15对5.55±2.32ml/分钟)没有显著改变。未观察到奈替米星或妥布霉素的中央或稳态分布容积有变化。在任何一种氨基糖苷类抗生素存在的情况下,血液透析患者中哌拉西林的处置均未改变。虽然奈替米星给药无需调整剂量,但当与哌拉西林同时给予血液透析患者时,妥布霉素应更频繁给药,以避免出现亚治疗浓度的持续时间过长。